FLUMIST TRIVALENT INFLUENZA INTRANASAL VACCINE [SIN17298P]
Active ingredients: INFLUENZA VIRUS (NH) A/DARWIN/1454/2025 (H3N2)-LIKE VIRUS (A/DARWIN/1369/2025) | INFLUENZA VIRUS (NH) A/MISSOURI/11/2025 (H1N1)PDM09-LIKE VIRUS (A/SWITZERLAND/6849/2025) | INFLUENZA VIRUS (NH) B/TOKYO/EIS13-175/2025 (B/VICTORIA LINEAGE)-LIKE VIRUS (B/PERTH/115/2025)
Last updated on 9 October 2026
Product Info
FLUMIST TRIVALENT INFLUENZA INTRANASAL VACCINE
[SIN17298P]
Product information
Active Ingredient and Strength | INFLUENZA VIRUS (NH) A/DARWIN/1454/2025 (H3N2)-LIKE VIRUS (A/DARWIN/1369/2025) - 7 ± 0.5 LOG10 FFU/DOSE |
Dosage Form | SPRAY |
Manufacturer and Country | ASTRAZENECA PHARMACEUTICALS LP - UNITED STATES |
Registration Number | SIN17298P |
Licence Holder | ASTRAZENECA SINGAPORE PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | J07BB03 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
1 INDICATIONS AND USAGE
FluMist® Trivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine [see Description (11) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information].
FluMist Trivalent is approved for use in persons 2 through 49 years of age [see Clinical Studies (14) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information].
Dosing
2 DOSAGE AND ADMINISTRATION
For intranasal use.
2.1 Dosing Information
Administer FluMist Trivalent according to the following schedule:
2.2 Administration Instructions
Each sprayer contains a single dose (0.2 mL) of FluMist Trivalent; administer approximately one half of the contents of the single-dose intranasal sprayer into each nostril (each sprayer contains 0.2 mL of vaccine). Refer to Figure 1 for step-by-step administration instructions. Following administration, dispose of the sprayer according to the standard procedures for medical waste (e.g., sharps container or biohazard container).
Contraindications
4 CONTRAINDICATIONS
4.1 Severe Allergic Reactions
Do not administer FluMist Trivalent to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine [see Description (11) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information] including egg protein, or after a previous dose of any influenza vaccine.
4.2 Concomitant Aspirin Therapy and Reye’s Syndrome in Children and Adolescents
Do not administer FluMist Trivalent to children and adolescents through 17 years of age who are receiving aspirin therapy or aspirin-containing therapy because of the association of Reye’s syndrome with aspirin and wild-type influenza infection [see Drug Interactions (7.1) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information].